Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells 10,500 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 10,500 shares of Kestra Medical Technologies stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $26.69, for a total value of $280,245.00. Following the transaction, the insider owned 136,633 shares of the company’s stock, valued at $3,646,734.77. The trade was a 7.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Kestra Medical Technologies Stock Performance

Shares of KMTS traded down $0.45 during mid-day trading on Wednesday, reaching $26.52. The company’s stock had a trading volume of 489,936 shares, compared to its average volume of 289,819. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.26. The stock has a market cap of $1.55 billion and a P/E ratio of -8.37. Kestra Medical Technologies, Ltd. has a 1-year low of $13.25 and a 1-year high of $30.00. The business has a 50-day simple moving average of $26.29 and a two-hundred day simple moving average of $21.37.

Analysts Set New Price Targets

A number of research analysts recently commented on KMTS shares. Stifel Nicolaus set a $30.00 price target on shares of Kestra Medical Technologies in a research note on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Piper Sandler boosted their price target on Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Wells Fargo & Company increased their price target on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Finally, BTIG Research started coverage on Kestra Medical Technologies in a research note on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $29.14.

Institutional Investors Weigh In On Kestra Medical Technologies

Several institutional investors and hedge funds have recently made changes to their positions in the business. Yu Fan bought a new position in Kestra Medical Technologies during the first quarter worth $56,880,000. Alliancebernstein L.P. raised its stake in shares of Kestra Medical Technologies by 13.7% in the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after purchasing an additional 179,885 shares during the last quarter. Eventide Asset Management LLC lifted its stake in Kestra Medical Technologies by 285.7% during the 2nd quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock valued at $17,584,000 after acquiring an additional 785,557 shares in the last quarter. Brown Advisory Inc. boosted its holdings in Kestra Medical Technologies by 5.4% during the second quarter. Brown Advisory Inc. now owns 580,025 shares of the company’s stock worth $9,617,000 after purchasing an additional 29,607 shares during the last quarter. Finally, Millennium Management LLC bought a new position in shares of Kestra Medical Technologies in the first quarter valued at approximately $11,036,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.